Emergency Medicine | Page 36 of 62 | Links Medicus Content Curation & Alerts in Medicine

NIH update💥💥
Therapeutic Management of Nonhospitalized Adults With #COVID19 #TwitteRx #medtwitter #TwitteRx #MedEd https://t.co/QpKsVJArUj pic.twitter.com/HKb81dB5b8

— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) February 1, 2022

Perspective: The ongoing saga of normal saline vs. balanced fluids.

2 Feb, 2022 | 08:43h | UTC

The ongoing saga of normal saline versus balanced fluids – First10EM

Original studies:

RCT: In critically ill adults, using a balanced multielectrolyte solution did not lower the risk of death or acute kidney injury compared to standard saline.

Balanced Crystalloids versus Saline in Critically Ill Adults — A Systematic Review with Meta-Analysis – NEJM Evidence

BaSICS RCT: Among critically ill patients requiring fluid therapy, treatment with a balanced solution did not lead to reduced mortality compared to a 0.9% saline solution.

BaSICS RCT: Among critically ill patients requiring fluid therapy, there was no difference in mortality with slower (333 mL/h) vs. faster (999 mL/h) intravenous fluid bolus rates.

Cochrane Review: Buffered Solutions Do Not Improve Mortality in Critically Ill Adults and Children Compared to 0,9% Saline

Takotsubo Syndrome: A review of presentation, diagnosis and management.

2 Feb, 2022 | 08:25h | UTC

Takotsubo Syndrome: A Review of Presentation, Diagnosis and Management – Clinical Medicine Insights: Cardiology

Middle-aged and older women are being diagnosed with Takotsubo Syndrome more frequently, up to 10 times more often, than younger women or men of any age.

International Expert Consensus Document on Takotsubo Syndrome

International Registry: 16.6% of Patients with Takotsubo Syndrome Have Underlying Malignancy

Systematic Review: Long-Term Prognosis and Outcome Predictors in Takotsubo Syndrome

Cohort Study: Hospital Readmission Following Takotsubo Syndrome

SCAI SHOCK Cardiogenic Shock Classification Expert Consensus Update.

1 Feb, 2022 | 09:53h | UTC

SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021 – JSCAI

News Release: SCAI releases updated expert consensus to SCAI SHOCK classification – Society for Cardiovascular Angiography and Interventions

Commentaries:

SCAI SHOCK: Update Refines Cardiogenic Shock Classification – TCTMD

SCAI Releases Updated Expert Consensus to SCAI SHOCK Classification – American College of Cardiology

Commentaries on Twitter

.@SCAI SHOCK stage is an indication of shock severity & comprises one component of mortality risk prediction in pts w/ CS, along w/ etiology/phenotype & other risk modifiers; a 3-axis model of risk stratification in CS has been proposed. Learn more: https://t.co/tnh2JFhHzN #JACC pic.twitter.com/yK2ye9wcd0

— JACC Journals (@JACCJournals) January 31, 2022

SCAI SHOCK Stage Classification Expert Consensus Update released today in the inaugural issue of @MyJSCAI and also in @JACCJournals. Thank you to endorsing societies @ACCinTouch @american_heart @ACEPNow @escardio @ACVCPresident @ISHLT @SCCM @STS_CTsurgery https://t.co/GHrYn5I5WO pic.twitter.com/Y0mKC0zONu

— SCAI (@SCAI) January 31, 2022

The Lancet Commission: Experts warn of the increasing overmedicalization of death, call for radical rethink of how society cares for dying people.

1 Feb, 2022 | 09:55h | UTC

News Release: THE LANCET: Experts warn of the increasing overmedicalization of death, call for radical rethink of how society cares for dying people

Homepage: Lancet Commission on the Value of Death (free registration required for all articles)

Report of the Lancet Commission on the Value of Death: bringing death back into life

The precariousness of balancing life and death

Ros Taylor: seeing palliative care as relational

Commentary on Twitter (thread – click for more)

Increasing overmedicalisation at the end of life is denying people & their families a good death.

Towards a compassionate community model: The Lancet #ValueofDeath Commission calls for a radical rethink of care for the dying & attitudes to death. https://t.co/DpJiu1tOcV pic.twitter.com/FU9MgCO1J6

— The Lancet (@TheLancet) January 31, 2022

Consensus: Nephrotoxins and acute kidney injury.

1 Feb, 2022 | 08:46h | UTC

Nephrotoxins and acute kidney injury – The consensus of the Taiwan acute kidney injury Task Force – Journal of the Formosan Medical Association

M-A: Vasopressin and glucocorticoids for in-hospital cardiac arrest.

1 Feb, 2022 | 08:43h | UTC

Vasopressin and glucocorticoids for in-hospital cardiac arrest: A systematic review and meta-analysis of individual participant data – Resuscitation

Commentary on Twitter

Systemic review and meta analysis post VAM-IHCA.
▶️ Moderate certainty for benefit with steroids and vasopressin on ROSC
▶️ Less certainty for longer term outcomes @mathiasholmb @LarsWAndersen1 @AsgerGranfeldt https://t.co/K3jZ1gBs1h

— Critical Care Reviews (@CritCareReviews) January 4, 2022

Review: Multidisciplinary management of tracheobronchial injury.

1 Feb, 2022 | 08:17h | UTC

Multidisciplinary management of tracheobronchial injury – European Respiratory Review

FDA halts use of antibody drugs that don’t work vs. Omicron.

30 Jan, 2022 | 14:35h | UTC

FDA halts use of antibody drugs that don’t work vs. omicron – Associated Press

Guideline Summary: Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.

30 Jan, 2022 | 14:11h | UTC

Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy – JCO Oncology Practice

Original Article: ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.

Clinical practice guideline on immune checkpoint inhibitor-related adverse events.

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)

RCT: Hyperimmune immunoglobulin did not improve outcomes in hospitalized patients with COVID-19.

28 Jan, 2022 | 08:42h | UTC

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial – The Lancet

Commentaries:

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19 – The Lancet

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 – NIH News Releases

Evidence-Based Guidelines for Prehospital Pain Management.

28 Jan, 2022 | 08:24h | UTC

Evidence-Based Guidelines for Prehospital Pain Management: Recommendations – Prehospital Emergency Care

Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

27 Jan, 2022 | 10:03h | UTC

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant – New England Journal of Medicine

Commentary: Current anti-COVID pills work well against omicron, but antibody drugs are less effective, study finds – University of Wisconsin-Madison

Commentary on Twitter

Investigators assessed the in vitro activities of seven monoclonal antibodies & three antiviral drugs against #COVID19 variants. All antibodies showed no or weak neutralizing activity against omicron; two drugs effective at omicron neutralization. https://t.co/rOZzmtsDZS pic.twitter.com/shfKDW6r5q

— NEJM (@NEJM) January 26, 2022